Article Details
Retrieved on: 2021-03-05 01:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Aptamer will continue to work with AstraZeneca on the development of aptamer-based technologies for CVRM therapies. Arron Tolley, CEO of Aptamer ...
Article found on: www.epmmagazine.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here